Phaseline

Targets › PTHR1

PTHR1 (Parathyroid hormone/parathyroid hormone-related peptide receptor): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 1 Phase 3, 1 Phase 4; Metabolic and endocrine, Other; next expected readout Nov 2026.

G protein-coupled receptor for parathyroid hormone (PTH) and for parathyroid hormone-related peptide (PTHLH). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase (cAMP). (UniProt, Q03431)

Open in Phaseline: the race on PTHR1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of BaghdadParathyroid Hormone (PTH)
Parathyroid hormone receptor 1 agonist; promotes bone formation and osteoblast activity
PTHR1Phase 4Maxillary Sinus AugmentationNov 2026
MBX BiosciencesCanvuparatide
PTH analog (parathyroid hormone analog)
PTHR1Phase 3HypoparathyroidismJan 2028

Conditions

Hypoparathyroidism (1) Maxillary Sinus Augmentation (1)

Modalities

protein or peptide (1)

Companies

MBX Biosciences (1) University of Baghdad (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.